September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Incidence and risk factor of elevated intraocular pressure after dexamethasone intravitreal implant
Author Affiliations & Notes
  • Jiwoong Lee
    Ophthalmology, Pusan National University, Busan, Korea (the Republic of)
  • Hyocheol Lim
    Ophthalmology, Pusan National University, Busan, Korea (the Republic of)
  • Footnotes
    Commercial Relationships   Jiwoong Lee, None; Hyocheol Lim, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 3284. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Jiwoong Lee, Hyocheol Lim; Incidence and risk factor of elevated intraocular pressure after dexamethasone intravitreal implant. Invest. Ophthalmol. Vis. Sci. 2016;57(12):3284.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To report the incidence of intraocular pressure (IOP) elevation and to identify the risk factors for IOP elevation after intravitreal dexamethasone 0.7mg (Ozurdex®) Implant.

Methods : A total 90 eyes of 83 patients who underwent intravitreal dexamethasone implantation and who were followed for ≥ 1 month were included. IOP elevation was defined as a pressure > 21 mmHg at some time during follow-up.

Results : Twenty-seven eyes (30%) had an IOP greater than 21mmHg after dexamethasone intravitreal implant. The incidence of IOP elevation increases rapidly at 2~3 months after dexamethasone intravitreal implant. The Kaplan-Meier estimated incidence of IOP elevation was 26.8 ± 5.1% (mean±standard error) at 81 days. A Cox multivariate analysis showed the significant risk factors for IOP elevation to be age < 55 years (P = 0.023), baseline IOP ≥ 15mmHg (P = 0.002), a history of intraocular surgery (P<0.001), and diabetic retinopathy (P = 0.026).

Conclusions : This study demonstrates the incidence of IOP elevation to be 26.8%, and describes the risk factors related to IOP elevation. Clinicians should be cautious about the possibility of IOP elevation after intravitreal dexamethasone implant, especially in the presence of identified risk factors.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×